Subsequently, MSCs were also used for tissue toxicity such as hemorrhagic cystitis, pneumomediastinum and perforated colon. 8 Responses were seen in half of the patients, although many subsequently died from infection. MSCs reduced alloreactivity in MLCs in vitro equally effectively, irrespective of whether they were autologous or HLA mismatched. 5 This has also been confirmed in vivo, in which responses in GVHD were the same regardless of whether the MSCs were HLA identical, HLA haploidentical or HLA mismatched.
Here, we report a patient with myelofibrosis who was treated with MSCs for severe hemorrhage. This 61-year-old male underwent allogeneic hematopoietic SCT from an HLA-A, -B and -DRb1 genomically identical unrelated donor. He received conditioning with fludarabine (30 mg/m 2 ) for 6 consecutive days, followed by BU (4 mg/kg/day) for 2 consecutive days and antithymocyte globulin (5.5 mg/kg). He received a BM graft containing 1.8 Â 10 8 nucleated cells per kg and 1.8 Â 10 6 CD34 þ cells per kg. He received CYA and 'short' MTX as immunosuppressive treatment. His total WBC count fell below 0.1 Â 10 9 cells per L on day þ 11. Except for an increase in bilirubin on day þ 4, thought to be due to hepatotoxicity, his post transplant course was uneventful. On day þ 12, he started to bleed from the nose and gastrointestinal tract. During the next 5 days, he received in total 17 U of erythrocytes, 7 U of fresh frozen plasma and 12 U of platelets, and had a constant platelet level below 5 Â 10 9 cells per L. Hb level was maintained between 73 and 97 g/L. On day þ 16, he was also given a G-CSF-mobilized granulocyte transfusion without any increment in neutrophil count. He had constant melena and an abdominal computed tomography scan revealed diffuse hemorrhaging from the proximal jejunum. Owing to previous portal and mesenteric thrombosis, he had undergone surgery, receiving a mesenteric caval shunt in the year 2000 and developing several varicose mesenteric veins. On this occasion, surgery to stop the bleeding was not possible for technical reasons and the platelet levels were o5 Â 10 9 cells per L. He had multispecific anti-HLA antibodies and was refractory to platelets. Because of life-threatening hemorrhage and no other treatment option, MSCs at 2 Â 10 6 cells per kg (pooled from two donors) were given on day þ 18.
Subsequent to the MSC infusion, the patient had no further hemorrhages and a nose pack was removed. MSCs were taken from the BM and cultured in 10% FCS according to our expansion protocol. 5 We decided to use pooled MSCs from two donors, because previous experience using single donors had shown that there was a response rate of B50%. 7, 8 We had found that in vitro immunomodulation in MLCs improved if MSCs from several donors were pooled. 9 The patient had his last melena 2 days after MSC infusion, and thereafter, stool was normal and fecal hemoglobulin was negative (Table 1) . He was discharged from hospital on day 33 after transplantation. Subsequently, he developed graft failure. He has been readmitted to the transplantation ward on four occasions because of hemorrhage (Table 1) This case report suggests that MSCs can be used for severe hemorrhaging that does not respond to conventional therapy. The antiinflammatory and tissue repairing effects by MSCs are probably not the only explanation in this case, because the positive effects of MSCs on bleeding were quite rapid. One could speculate that MSCs may also induce vasoconstriction and coagulation. We wanted to alert our colleagues to this therapeutic possibility. To prove the efficacy of this approach, a control study is needed, which will require a major multicenter effort.
In addition, we have now treated 12 patients for severe hemorrhagic cystitis. Seven of these patients have been reported previously. 8 Two patients had reduced transfusion requirements after MSC infusion, but died of multiorgan failure. In 8 of the 10 remaining patients, gross hematuria disappeared after a median of 3 (1-14) days. Two patients did not respond to MSC infusion. The two most recent responders received pooled MSCs.
MSCs had a dramatic effect on tissue toxicity in some patients. In other patients, there was no obvious effect. Further studies are required to answer the question of why some patients respond to MSC therapy while others do not. MSC donor DNA has been detected in target tissues of patients with GVHD and at the site of injury of tissue toxicity. 7, 8 This is also in accordance with experience in experimental animals, in which MSCs were demonstrated to home into damaged tissue. 10 We have tried for the first time to pool MSCs from several donors. Additional studies are needed in order to determine whether this can improve the response rate in patients with tissue toxicity and GVHD.
To conclude, treatment with MSCs is a therapeutic option in patients with severe hemorrhage and merits further investigation.
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